Arrakis Therapeutics

Arrakis Therapeutics is a biopharmaceutical company on a mission to revolutionize medicine by bringing powerful new RNA-targeted small molecule (rSM) therapies to millions of patients. Founded in 2015 and headquartered in the United States, Arrakis aims to extend small-molecule medicines into new realms of biology by targeting RNA, which has previously been considered "undruggable". The company's approach, led by a team of skilled scientists and drug development leaders, focuses on discovering small-molecule compounds that act directly on RNA, paving the way for a new path in the discovery of RNA-targeted medicines. In April 2019, Arrakis secured a significant $75.00M Series B investment with participation from notable investors including Advent Life Sciences, Canaan Partners, Alexandria Venture Investments, Celgene, Nextech Invest, Omega Funds, VenBio Partners, WuXi AppTec, OUP (Osage University Partners), and Henri Termeer. This latest investment underscores the confidence of the investor community in Arrakis' innovative approach and the potential impact their platform can have on improving patient outcomes. Arrakis' pioneering efforts in the emerging field of RNA-targeted small molecule therapies demonstrate a commitment to pushing the frontier of scientific discovery with the ultimate goal of developing powerful new therapies for patients globally. Their groundbreaking work has the potential to unlock hundreds of biological targets not currently accessible to medicine, offering hope for addressing previously unmet medical needs.